AstraZeneca’s Imfinzi survival win shores up the one lung cancer advantage it has

AstraZeneca’s immunotherapy Imfinzi already has an FDA approval for inoperable lung cancer patients who've responded to chemo and radiation—and that's something none of its rivals will be…
Read the full story: FiercePharma: Pharma